Spotlight

In the July-August issue of Prescrire International: emtricitabine + tenofovir disoproxil (Truvada° and other brands) for prevention of HIV infection in adolescents

Summary

In seronegative adults at risk of sexually acquired HIV infection, in particular those who engage in high-risk sexual behaviours, the emtricitabine + tenofovir disoproxil fixed-dose combination (Truvada° or other brands) markedly reduces but does not eliminate the risk of contracting HIV infection.
The combination has been authorised in the European Union for the prevention of HIV infection in adolescents whose sex practices place them at high risk of becoming infected.
POSSIBLY HELPFUL The emtricitabine + tenofovir disoproxil combination has undergone inadequate evaluation as HIV prophylaxis in adolescents. However, based on extrapolation of the data obtained in adults, this option appears worth offering to adolescents whose sex practices place them at particularly high risk of contracting HIV infection. It is important to inform them that this treatment does not provide complete protection and to stress the importance of treatment adherence. They should also be strongly encouraged to use condoms and to undergo regular screening for sexually transmitted infections, including HIV.

Full text available for free download.